Q32 Bio reports positive Phase 2a bempikibart results in alopecia areata

Q32 Bio Inc. announced on July 13, 2026 positive 36-week topline results from Part B of its SIGNAL-AA Phase 2a trial evaluating bempikibart in patients with severe or very severe alopecia areata. The mean percent reduction in SALT score from baseline was 35.3% in the mITT analysis at Week 36.¹ In that same analysis, 40.0% (10/25) of patients achieved a SALT-20 response, compared with 30.3% (10/33) in the intent-to-treat analysis.¹

The trial enrolled 33 patients with baseline SALT scores of 50-100 and a maximum current-episode duration of four years, and 36.4% of enrolled patients had prior oral JAK inhibitor exposure.¹ Dosing consisted of a loading regimen of 200mg weekly for four doses, followed by 200mg every other week for 32 weeks, for a total 36-week dosing period.¹

On safety, bempikibart showed a generally well-tolerated profile consistent with prior studies, with no new safety signals and no serious adverse events or Grade 3 or higher treatment-related adverse events.¹ The most common treatment-emergent adverse event was injection site reaction (36.3%), mostly single events, with all ISRs mild and resolving without intervention.¹

Q32 Bio said it intends to advance bempikibart into a registration-directed program in the first half of 2027 and plans to share full Part B results at a future medical meeting.¹

In the same Form 8-K, under a "Corporate Updates" section covering Item 8.01, the company disclosed that on June 24, 2026 it paid off the remaining balance of approximately $6.8 million under its Loan and Security Agreement with Silicon Valley Bank, a division of First-Citizens Bank & Trust Company, and that the loan agreement has been terminated.¹ A separate 8-K filed the same day contained an investor presentation with additional detail on the Part B data, including baseline demographics and pharmacokinetic results.